Clinical Scorecard: A comparative analysis of magnetic sphincter augmentation versus Nissen fundoplication for treating gastroesophageal reflux disease (GERD)
At a Glance
Category
Detail
Condition
Gastroesophageal reflux disease (GERD)
Key Mechanisms
GERD involves reflux of stomach acid into the esophagus due to lower esophageal sphincter (LES) dysfunction; treatments aim to restore LES function and prevent acid reflux.
Target Population
Patients with GERD symptoms including acid reflux, heartburn, throat discomfort, coughing, and chest pain; excluding those with large hiatal hernias (>2 cm), severe esophagitis (grade C/D), dysphagia, esophageal motility disorders, or prior relevant surgeries.
Care Setting
Surgical care in specialized centers with laparoscopic expertise.
Key Highlights
Magnetic sphincter augmentation (MSA) uses a magnetic ring device (LINX system) to augment LES pressure and prevent reflux while allowing food passage.
Laparoscopic Nissen fundoplication (LNF) is a well-established surgical technique repairing hiatal hernias to control reflux.
MSA shows comparable safety and efficacy to LNF with FDA approval since 2012 and guideline endorsement by SAGES.
Guideline-Based Recommendations
Diagnosis
Use gastroscopy, high-resolution manometry (HRM), contrast-enhanced ultrasonography, and GERD-Q questionnaire for preoperative evaluation.
Perform 24-hour pH monitoring before and after MSA surgery as per clinical trial protocols.
Management
Consider MSA or LNF as surgical options for patients with GERD refractory to medical therapy or with anatomical indications.
Exclude patients with large hiatal hernias (>2 cm), severe esophagitis (grade C/D), dysphagia, esophageal motility abnormalities, or those requiring future MRI from MSA candidacy.
Perform all surgeries laparoscopically by experienced surgeons preserving vagus nerve and carefully dissecting esophageal hiatus.
Monitoring & Follow-up
Postoperative follow-up includes chest X-ray and gastroscopy at one year after MSA.
Monitor symptom relief, acid exposure, and device function through clinical and imaging assessments.
Risks
Long-term PPI use carries risks affecting quality of life, motivating surgical alternatives.
MSA contraindicated in patients with dysphagia, esophageal motility disorders, large hiatal hernias, or severe esophagitis.
Potential surgical risks include injury to vagus nerve, pleura preservation challenges, and need for precise device sizing.
Patient & Prescribing Data
40 patients with GERD matched for age, gender, BMI, symptom duration, and baseline LES pressure; 16 underwent MSA and 24 underwent LNF.
Both MSA and LNF groups showed comparable baseline characteristics; MSA requires precise intraoperative sizing of the magnetic device; ongoing clinical trials support MSA efficacy and safety.
Clinical Best Practices
Conduct thorough preoperative evaluation including gastroscopy, HRM, contrast-enhanced ultrasound, and GERD-Q scoring.
Select surgical candidates carefully excluding those with contraindications to MSA.
Perform laparoscopic surgery with careful dissection preserving vagus nerve and pleura.
Use esophageal sizing device intraoperatively to select appropriate MSA device size.
Close hiatal hernia defect with non-absorbable sutures ensuring adequate esophageal passage.
Follow standardized postoperative monitoring protocols including imaging and symptom assessment.
The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.
